Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07762391
Pelvic Floor Muscle Exercise and Progressive Muscle Relaxation for Stress Urinary IncontinenceKaramanoğlu Mehmetbey UniversityCompletedNot Applicable
NCT07762391Completed
Not Applicable
Pelvic Floor Muscle Exercise and Progressive Muscle Relaxation for Stress Urinar...Karamanoğlu Mehmetbey Uni...
NCT07763483
Do Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?Hospices Civils de LyonNot Yet Recruiting
NCT07763483Not Yet Recruiting
—
Do Endocrine Disruptors Accumulate in Children Undergoing Paediatric Dialysis?Hospices Civils de Lyon
NCT07764250
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive ImpairmentShifa Tameer-e-Millat UniversityRecruitingNot Applicable
NCT07764250Recruiting
Not Applicable
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training i...Shifa Tameer-e-Millat Uni...
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
NCT07762794
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairHumacyte, Inc.Not Yet RecruitingPhase 4
NCT07762794Not Yet Recruiting
Phase 4
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real Worl...Humacyte, Inc.
NCT07762053
Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomonitor TonometerEyeCBetter CorporationNot Yet RecruitingNot Applicable
NCT07762053Not Yet Recruiting
Not Applicable
Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomon...EyeCBetter Corporation
NCT07763145
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy: A Randomized Control TrialHayatabad Medical ComplexNot Yet RecruitingNot Applicable
NCT07763145Not Yet Recruiting
Not Applicable
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resisti...Hayatabad Medical Complex
NCT07763574
Effects of Strength Training Combined With Sustainable Source of Omega-3 Fatty Acids on Muscle Strength and Cognitive Functions in Adults Controlled TrialGdansk University of Physical Education and SportEnrolling By InvitationNot Applicable
NCT07763574Enrolling By Invitation
Not Applicable
Effects of Strength Training Combined With Sustainable Source of Omega-3 Fatty A...Gdansk University of Phys...
NCT07763782
Dose-Response Structured Calf Muscle Pump Activation Strategies Versus Unsupervised Home WalksMTI UniversityNot Yet RecruitingNot Applicable
NCT07763782Not Yet Recruiting
Not Applicable
Dose-Response Structured Calf Muscle Pump Activation Strategies Versus Unsupervi...MTI University
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07764081
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764081Recruiting
—
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, N...
NCT07764016
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scoring in Patients With Femoropopliteal Arterial DiseaseCardionovum GmbHNot Yet RecruitingNot Applicable
NCT07764016Not Yet Recruiting
Not Applicable
DCB Outcomes After Non-Compliant Balloon Vessel Preparation With or Without Scor...Cardionovum GmbH
NCT07763496
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUPNot Yet RecruitingPhase 2
NCT07763496Not Yet Recruiting
Phase 2
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUP
NCT07762027
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus InfectionAssembly BiosciencesNot Yet RecruitingPhase 2
NCT07762027Not Yet Recruiting
Phase 2
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Part...Assembly Biosciences
NCT07762989
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longus Tendon AutograftGazi UniversityNot Yet Recruiting
NCT07762989Not Yet Recruiting
—
Donor Ankle Sensorimotor Recovery After ACL Reconstruction With a Peroneus Longu...Gazi University
NCT07762781
Impact of a Mobile Exercise Application on Sleep, Pain, and Fitness in Healthy AdultsTokat Gaziosmanpasa UniversityCompletedNot Applicable
NCT07762781Completed
Not Applicable
Impact of a Mobile Exercise Application on Sleep, Pain, and Fitness in Healthy A...Tokat Gaziosmanpasa Unive...
NCT07763171
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaGruppo Oncologico del Nord-OvestNot Yet RecruitingPhase 3
NCT07763171Not Yet Recruiting
Phase 3
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-neg...Gruppo Oncologico del Nor...
Result Breakdown
Not yet recruiting12 (60%)
Recruiting3 (15%)
Completed2 (10%)
Enrolling by invitation1 (5%)
Unknown1 (5%)
Active, not recruiting1 (5%)
not_applicable8 (40%)
Not Specified6 (30%)
Phase 12 (10%)
Phase 22 (10%)
Phase 41 (5%)
Phase 31 (5%)